Previous 10 | Next 10 |
Alnylam is rapidly becoming the leader in ATTR through its successful therapy, patisiran. Intellia has presented data showing even deeper reductions in TTR. Though early Intellia has the potential to show better clinical outcomes in patients with ATTR. For years, patient...
Atara has two possible regulatory approvals for tab-cel for PTLD; European approval expected Q4 of 2022 and BLA filing for U.S. territory to be updated in next quarter earnings call. Two data readouts of ATA188 for treatment of patients with progressive multiple sclerosis; Phase 1 MRI...
ImmunoGen announced that it will receive the FDA decision for mirvetuximab on November 28th. The deal with Oxford BioTechnologies will support further growth. ImmunoGen remains robust from a financial point of view. Two weeks ago, the leading biotech company ImmunoGen, I...
Why health care stocks may outperform the broader market in the long run. Is now the time to consider health care stocks? Why health care is still a good way for investors to play defense. Greg Bonnell: Many health care stocks are down from the highs put in e...
Results for both studies from the DISSOLVE phase 3 program, using SEL-212 for the treatment of patients with chronic refractory gout, are expected in Q1 of 2023. Potential to restore immune tolerance and target underlying cause of patients with primary biliary cirrhosis with use of Im...
Funding difficulties have definitely been priced into Clovis' share price. Clovis, though, has some interesting readouts due this year and in early 2023. If data is encouraging and new funding is announced, CLVS stock could rally sharply from present levels. Intro ...
BLA filing of SRP-9001 for the treatment of patients with DMD is expected in fall of 2022; If filing and review go well then FDA Accelerated approval possible mid-2023. The global market opportunity for Duchenne Muscular Dystrophy is expected to reach $4.11 billion by 2023. Sarept...
Elevated inflation, slowing global economic growth expectations, and reduced central bank liquidity remain the key economic considerations. The policy interest rate divergence between the U.S. and Europe is likely to increase amid heightened recession risk in Europe. We expect mar...
The investment landscape has been much more difficult for most sustainable portfolios since the fourth quarter of last year. One thing that we know is that the sustainability challenges that these stocks are connected to haven’t gone away. If anything, the economic challeng...
A convergence of technologies is set to revolutionize how physicians examine the body for signs of cancer. there is every reason to expect that future evolution of robotic endoluminal procedures could include the ability during the procedure to treat the cancer, either via ablation or...
News, Short Squeeze, Breakout and More Instantly...
Principal Healthcare Innovators Index ETF Company Name:
BTEC Stock Symbol:
NASDAQ Market:
2024-07-06 22:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-07 05:46:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-05-16 17:28:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...